Protective Effect of Salvianolic Acid B in Acetic Acid-Induced Experimental Colitis in a Mouse Model

Mydhili Govindarasu,Ekambaram Gayathiri,Govindasamy Rajakumar,Pari Abirami,Manju Vaiyapuri,Muthu Thiruvengadam,Saad Alghamdi,Mariyappan Palani,Mazen Almehmadi,Sami Alyahya,Azzah M Bannunah,Mohammad Azam Ansari,Mohammad N Alomary

doi:10.3390/pr9091589

Abstract

In its prominent experimental studies salvianolic acid B (Sal B) is novel because of its well-defined, common physiological effects, which include anti-inflammatory, anti-depressant, cardioprotective, DNA protective, neuroprotective and hepatoprotective activity in experimental animals. Initially, Sal B was studied for its anti-inflammatory properties, used as a remedy for a wide range of disease conditions, but its specific efficacy on inflammatory bowel disease is still unclear. The aim of this current study was to understand the therapeutic potential of Sal B in an acetic acid (AA)—triggered experimental mouse colitis model. Colitis was triggered by intrarectal injection of 5% AA, and then laboratory animals were given Sal B (10, 20 and 40 μg/kg) for seven days. The ulcerated colonic mucosa was assessed by clinical experiment, macroscopical, biological and histopathological analysis. The results showed depleted SOD, CAT, GSH levels and consequential elevated MPO and MDA levels and aberrant crypt foci and mast cells were seen in the AA-induced colonic mucosa of experimental animals. The data obtained from this study demonstrate that a dose of 40 µg/kg showed an efficacious anti-ulcer effect against AA-induced experimental colitis. Based on its antioxidant efficacy, Sal B may therefore be useful as a therapeutic approach for ulcerative colitis.

Highlights

Compared with group 1 (Control), the % of body weight drastically decreased in the acetic acid (AA)-induced colitis group 2 mice
The minimal disease activity state was elevated in the AA-induced colitis group
The length of the colon is considered being inversely proportional to the severity of AA-induced experimental colitis

Summary

Introduction

Ulcerative colitis (UC) is a widespread significant complication of irritable bowel syndrome and chronic gastrointestinal tract immunological disorder that causes inexorable creativecommons.org/licenses/by/ 4.0/). Ulcerative colitis (UC) is a widespread significant complication of irritable bowel syndrome and chronic gastrointestinal tract immunological disorder that causes inexorable ulceration, tenesmus, diarrhea, bloody stools, inflammation in the intestine and colon and mucosal tissue damage [1,2,3]. 2.5 milliontenesmus, people in diarrhea, the United. By 2030, it is thatand the colon number ulceration, bloody inflammation inexpected the intestine andof people living with. Mucosal tissue damage [1,2,3]. Inflammatory bowel disease (IBD) affected about 2.5 million

Objectives

Methods

Results